• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Peacock Jonathan M bought $103,646 worth of shares (8,091 units at $12.81), increasing direct ownership by 4% to 202,715 units (SEC Form 4)

    4/29/25 5:58:18 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Peacock Jonathan M

    (Last) (First) (Middle)
    RADNOR CORPORATE CENTER, BUILDING ONE,
    SUITE 200, 100 MATSONFORD ROAD

    (Street)
    RADNOR PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Avantor, Inc. [ AVTR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/28/2025 P 8,091 A $12.81(1) 202,715 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the weighted average trading price of share purchased on the transaction date. The range for the purchase of the shares was $12.36 and $12.83.
    Remarks:
    /s/ Scott Baker, as Attorney-in-Fact 04/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    More analyst ratings

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/27/25 4:58:03 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/22/25 5:37:34 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/9/25 4:51:58 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AVTR
    SEC Filings

    View All

    EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.11% to 171,563 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/15/25 4:35:16 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, AMEA Couturier Christophe was granted 65,217 shares, increasing direct ownership by 45% to 211,271 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/12/25 5:04:18 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP & Chief Accounting Officer Eck Steven W sold $39,592 worth of shares (3,476 units at $11.39), decreasing direct ownership by 6% to 55,068 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/6/25 4:32:53 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Jefferies

    Jefferies downgraded Avantor from Buy to Hold

    8/1/25 1:45:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Goldman with a new price target

    Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

    4/29/25 8:05:35 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by TD Cowen with a new price target

    TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

    4/28/25 8:32:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reiterates Shareholder Value Creation Focus

    Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to Begin Role as CEO Next Week RADNOR, Pa., Aug. 11, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today issued the following statement in response to the letter issued by Engine Capital:  The Board of Directors is actively engaged in overseeing the setting and execution of the Company's strategy and is committed to always acting in the best inter

    8/11/25 9:33:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Engine Capital Sends Letter to Avantor's Board of Directors Regarding Opportunities to Improve Governance and Unlock Shareholder Value

    Believes Years of Self-Inflicted Issues Have Caused Avantor to Trade at a Meaningful Discount to its Intrinsic Value and Life Sciences Peers Contends the Board Has Failed to Remedy Operating Underperformance, Ineffective Cost Controls and Poor Capital Deployment – Resulting in Significant Value Destruction Over Every Relevant Period Makes Clear the Board Needs to Be Refreshed with New Directors with Successful Experience in Healthcare Distribution, Capital Allocation and Leadership at Relevant Companies Sees Path to Realizing 100% Upside in Share Price by End of 2027 by Prioritizing Cost Discipline, Operational Improvements, Portfolio Optimization and Immediate Share Repurchases Eng

    8/11/25 7:00:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    8/13/25 5:03:52 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Avantor Inc.

    SCHEDULE 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/13/25 4:58:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    8/1/25 9:00:18 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

    NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS

    7/23/24 7:17:00 PM ET
    $APO
    $AVTR
    $HIBB
    Investment Managers
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Announces Emmanuel Ligner as Next President and CEO

    Seasoned Executive with Proven Track Record of Value Creation in Life Sciences RADNOR, Pa., July 21, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that it has named Emmanuel Ligner, President and Chief Executive Officer, effective August 18, 2025. Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointme

    7/21/25 7:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Second Quarter 2025 Earnings Call on Friday, August 1, 2025

    RADNOR, Pa., June 27, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the

    6/27/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials